Endometrial Cancer

SLNB is a viable option for the surgical staging of endometrial cancer, demonstrating high diagnostic accuracy and sensitivity with minimal false negatives.

Among women with stage I endometrial cancer, TLH is equivalent to TAH in terms of disease-free survival, supporting the use of laparoscopic surgery.

Surgical pathology effectively identifies prognostic factors and spread patterns in Stage I endometrial carcinoma, supporting individualized postoperative therapy based on pathologic findings.

Laparoscopic surgical staging for uterine cancer is feasible and safe, showing fewer complications and shorter hospital stays compared to laparotomy

Carboplatin/Taxol is not inferior to Ifos/Taxol in terms of OS and significantly increases PFS, making it a new standard treatment for carcinosarcoma

The study did not demonstrate superiority or equivalence due to similar outcomes in both arms. The higher incidence of pelvic/para-aortic nodal failures in the VCB/C arm suggests the importance of pelvic RT in preventing regional recurrences.

Lenvatinib plus pembrolizumab significantly improves progression-free and overall survival compared to chemotherapy among patients with advanced endometrial cancer.

The TC regimen demonstrated noninferiority to TAP in terms of OS and PFS while offering a better toxicity profile, making it a suitable first-line treatment for advanced endometrial cancer

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer